Accuray CyberKnife® Platform Featured in New Studies Showcasing its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting

Core Insights - Accuray Incorporated announced new data on the CyberKnife System, highlighting its effectiveness in treating central nervous system (CNS) tumors, which are among the most fatal cancers in the U.S. [1][3] - The studies presented at the 2025 Radiosurgery Society meeting emphasize the long-term efficacy and expanding applications of the CyberKnife System in treating various conditions, including benign tumors and complex spinal issues [3][4]. Clinical Advances - The CyberKnife System utilizes stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) to deliver targeted radiation in one to five sessions, achieving high precision through advanced image guidance and adaptive delivery technology [2][3]. - A 25-year study on vestibular schwannoma treatment showed a local control rate of 89.3% and an overall survival rate of 97.1%, demonstrating the long-term efficacy of the CyberKnife System [4]. Treatment Innovations - A study on circumferential SBRT for spinal metastases indicated that this technique is safe and effective, achieving high local tumor control with minimal complications [5]. - Research on trigeminal neuralgia in elderly patients revealed that 90% experienced pain relief after treatment with the CyberKnife System, showcasing its potential for patients with limited surgical options [5][6]. - For occipital condyle metastasis, the CyberKnife System achieved a local tumor control rate of 93.8% over three years, providing significant pain relief and improving neurological symptoms [6]. Company Commitment - Accuray is dedicated to advancing radiation therapy technology to improve patient outcomes, focusing on innovative solutions for complex cases while enhancing treatment accessibility for a broader patient population [7].